Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
WSD0628
i
Other names:
WSD0628
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Wayshine Biopharm
Drug class:
ATM kinase inhibitor, Radiosensitiser
Related drugs:
‹
AZD1390 (5)
KU-55933 (2)
AZD0156 (0)
M3541 (0)
XRD-0394 (0)
M4076 (0)
crystalline hafnium oxide (0)
nimorazole (0)
KRC-01 (0)
AZD1390 (5)
KU-55933 (2)
AZD0156 (0)
M3541 (0)
XRD-0394 (0)
M4076 (0)
crystalline hafnium oxide (0)
nimorazole (0)
KRC-01 (0)
›
Associations
News
Trials
Filter by
Latest
10ms
Clinical Trial of the ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors (clinicaltrials.gov)
P1, N=67, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
10 months ago
Enrollment open • Combination therapy
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
IDH wild-type
|
WSD0628
11ms
Clinical Trial of the ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors (clinicaltrials.gov)
P1, N=67, Not yet recruiting, Mayo Clinic | Trial completion date: Oct 2028 --> Feb 2029 | Trial primary completion date: Oct 2027 --> Feb 2028
11 months ago
Trial completion date • Trial primary completion date • Combination therapy
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
IDH wild-type
|
WSD0628
1year
Clinical Trial of the ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors (clinicaltrials.gov)
P1, N=67, Not yet recruiting, Mayo Clinic | Trial primary completion date: Oct 2028 --> Oct 2027
1 year ago
Trial primary completion date • Combination therapy
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
IDH wild-type
|
WSD0628
over1year
Clinical Trial of the ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors (clinicaltrials.gov)
P1, N=67, Not yet recruiting, Mayo Clinic
over 1 year ago
New P1 trial • Combination therapy
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
IDH wild-type
|
WSD0628
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login